PA
TVTX icon

Perceptive Advisors’s Travere Therapeutics TVTX Stock Holding History

Perceptive Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-100,000
Closed -$3.31M – 185
2015
Q2 		$3.31M Buy
+100,000
New +$2.74M 0.2% 80

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Perceptive Advisors's TVTX Position: Q2 2026 in Review

Perceptive Advisors reduced its Travere Therapeutics (TVTX) stake by 9.4% in Q2 2026, selling an estimated $17.3M and leaving 3,752,574 shares worth $213M. The position accounts for 3.2% of the portfolio, ranked #8.

Perceptive Advisors first reported a position in TVTX in Q1 2014 and has held it in 45 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Perceptive Advisors held 3,752,574 shares of Travere Therapeutics worth $213M as of Q2 2026.
  • Perceptive Advisors sold 389,977 Travere Therapeutics shares in Q2 2026, an estimated $17.3M.
  • Travere Therapeutics made up 3.2% of Perceptive Advisors's portfolio in Q2 2026, its #8 holding.
  • Perceptive Advisors first reported a position in Travere Therapeutics in Q1 2014 and has held it in 45 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.